<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432021000500005</article-id>
<article-id pub-id-type="doi">10.7399/fh.11633</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Prevalencia y tipos de interacciones farmacológicas en pacientes pediátricos hospitalizados en la Ciudad de México]]></article-title>
<article-title xml:lang="en"><![CDATA[Prevalence and types of drug interactions in hospitalized pediatric patients in Mexico City]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vázquez-Cornejo]]></surname>
<given-names><![CDATA[Edmundo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Román-García]]></surname>
<given-names><![CDATA[Sandra Ivette]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales-Ríos]]></surname>
<given-names><![CDATA[Olga]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Infantil de México Federico Gómez Unidad Habilitada de Apoyo al Predictamen ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General de Zona 1 A &#8220;Dr. Rodolfo Antonio de Mucha Macías&#8221; ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2021</year>
</pub-date>
<volume>45</volume>
<numero>5</numero>
<fpage>234</fpage>
<lpage>239</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432021000500005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432021000500005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432021000500005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Las interacciones fármaco-fármaco pueden modificar el efecto terapéutico o la seguridad de los medicamentos usados en poblaciones pediátricas. Aunque el interés sobre interacciones potenciales en estos grupos etarios viene incrementando, aún es escasa la información sobre interacciones fármaco-fármaco que se manifiestan clínicamente en el paciente (reales). El propósito de este estudio fue explorar la prevalencia y características de las interacciones fármaco-fármaco potenciales y reales en pacientes ingresados en dos hospitales pediátricos de la Ciudad de México.  Método: Se llevó a cabo un estudio transversal en expedientes de pacientes atendidos en servicios críticos, oncológicos, de quemados y otros no críticos por un médico residente de pediatría en ambos hospitales. Se usó Micromedex® como fuente de datos de interacciones potenciales, luego se estimó su prevalencia por paciente, gravedad y nivel de evidencia. Adicionalmente, se determinó la causalidad de las interacciones fármaco-fármaco con diversos desenlaces clínicos de los pacientes hospitalizados mediante la Drug Interaction Probability Scale, y finalmente se clasificaron por gravedad.  Resultados: La prevalencia observada de pacientes hospitalizados con una o más interacciones fármaco-fármaco potenciales fue del 61,3% (52,5-70,4%), mientras que la prevalencia de interacciones fármaco-fármaco reales fue del 3,6% (0,1-7,1%). Entre las interacciones potenciales, el 60,5% se consideraron importantes y sólo el 5,1% contraindicadas. En general, las interacciones fármaco-fármaco potenciales fueron más comunes en los servicios de cuidados intensivos y de quemados. Los principales grupos farmacológicos involucrados en interacciones potenciales fueron agentes analgésicos opioides, antibióticos y neurológicos. Cuatro interacciones reales requirieron modificación de la farmacoterapia y una prolongó la estancia hospitalaria.  Conclusiones: Las interacciones potenciales fueron comunes en los pacientes pediátricos estudiados, mientras que la frecuencia de interacciones reales fue baja; sin embargo, sus consecuencias requirieron acciones médicas adicionales a la monitorización habitual. Se requiere más información sobre las interacciones reales, aquellas referidas a faltas de eficacia podrían estar subestimadas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: Drug-drug interactions may modify the therapeutic effect or the safety profile of the medicines used in pediatric populations. Although interest on potential drug interactions in these age groups has increased, information on clinically relevant drug-drug interactions is still scarce. The aim of this study was to explore the prevalence and characteristics of potential and clinically relevant drug-drug interactions among pediatric patients hospitalized in two pediatric hospitals of Mexico City.  Method: A cross-sectional study was conducted on patient records in critical, oncological, burns and other non-critical services by a pediatric resident physician at both hospitals. Micromedex® was used as a source of potential drug-drug interactions data. Subsequently, each interaction&#8217;s prevalence, severity and evidence level were estimated. Additionally, drug-drug interaction causality with regard to diverse clinical outcomes of hospitalized patients was determined through the Drug Interaction Probability Scale. The clinical consequences of each interaction were classified by severity.  Results: The observed prevalence of one or more potential drug-drug interactions in hospitalized patients was 61.3% (52.2-70.4%), whilst the prevalence of real drug-drug interactions was 3.6% (0.1-7.1%). Of potential drug-drug interactions, 60.5% were considered major and only 5.1% contraindicated. These were generally more common in intensive care and burn units. The main pharmacological agents involved in potential drug-drug interactions were opioids analgesics and anti-infective and neurologic agents. Four clinically relevant drug-drug interactions required a regimen change and another prompted an extension of the patient&#8217;s hospital stay.  Conclusions: Potential drug-drug interactions were common in the pediatric patients studied, whereas the frequency of real drug-drug interactions was low. However, some drug-drug interactions required medical actions in addition to routine monitoring. More information is needed on real drug-drug interactions as those related to failed efficacy might be underestimated.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Interacciones farmacológicas]]></kwd>
<kwd lng="es"><![CDATA[Seguridad del paciente]]></kwd>
<kwd lng="es"><![CDATA[Relevancia clínica]]></kwd>
<kwd lng="es"><![CDATA[Pediatría]]></kwd>
<kwd lng="es"><![CDATA[Reacción adversa a medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Hospitales pediátricos]]></kwd>
<kwd lng="en"><![CDATA[Drug interactions]]></kwd>
<kwd lng="en"><![CDATA[Patient safety]]></kwd>
<kwd lng="en"><![CDATA[Clinical relevance]]></kwd>
<kwd lng="en"><![CDATA[Pediatrics]]></kwd>
<kwd lng="en"><![CDATA[Adverse drug reaction]]></kwd>
<kwd lng="en"><![CDATA[Pediatric hospitals]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenbaum]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Developmental pharmacokinetics in pediatric populations]]></article-title>
<source><![CDATA[J Pediatr Pharmacol Ther]]></source>
<year>2014</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>262-76</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tejada]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Arteta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2011</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>53-72</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Moretti]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Leone]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions]]></article-title>
<source><![CDATA[Expert Opin Drug Saf]]></source>
<year>2012</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>83-94</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salerno]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Burckart]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2019</year>
<volume>105</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1067-70</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[WY]]></given-names>
</name>
<name>
<surname><![CDATA[Richardson]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Westbrook]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Baysari]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2018</year>
<volume>74</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-27</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salem]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rostami-Hodjegan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Do children have the same vulnerability to metabolic drug&#8211;drug interactions as adults? A critical analysis of the literature]]></article-title>
<source><![CDATA[J Clin Pharmacol]]></source>
<year>2013</year>
<volume>53</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>559-66</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Feinstein]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Morrison]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zuppa]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Feudtner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children&#8217;s Hospitals]]></article-title>
<source><![CDATA[Pediatr Crit Care Med]]></source>
<year>2016</year>
<volume>17</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>e218-28</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales-Ríos]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Jasso-Gutiérrez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes-López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Garduño-Espinosa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz-Hernández]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential drug-drug interactions and their risk factors in pediatric patients admitted to the emergency department of a tertiary care hospital in Mexico]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2018</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández de Palencia Espinosa]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Carrasco]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Fuster Soler]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz Merino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De la Rubia Nieto]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Espuny Miró]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacoepidemiological study of drug-drug interactions in onco-hematological pediatric patients]]></article-title>
<source><![CDATA[Int J Clin Pharm]]></source>
<year>2014</year>
<volume>36</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1160-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feinstein]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zhong]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Feudtner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential drug-drug interactions in infant, child, and adolescent patients in children&#8217;s hospitals]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>2015</year>
<volume>135</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e99-e108</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holm]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Eiermann]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kimland]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mannheimer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of potential drug-drug interactions in Swedish pediatric outpatients]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2019</year>
<volume>14</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lebowitz]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Olson]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Harper]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Bourgeois]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-Drug Interactions Among Hospitalized Children Receiving Chronic Antiepileptic Drug Therapy]]></article-title>
<source><![CDATA[Hosp Pediatr]]></source>
<year>2016</year>
<volume>6</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>282-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yen]]></surname>
<given-names><![CDATA[YT]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[PY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential drugdrug interactions in pediatric outpatient prescriptions for newborns and infants]]></article-title>
<source><![CDATA[Comput Methods Programs Biomed]]></source>
<year>2014</year>
<volume>113</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-22</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balk]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[van der Sijs]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
<name>
<surname><![CDATA[van Gelder]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Janssen]]></surname>
<given-names><![CDATA[JJB]]></given-names>
</name>
<name>
<surname><![CDATA[van der Sluis]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[van Leeuwen]]></surname>
<given-names><![CDATA[RWF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-drug interactions in pediatric oncology patients]]></article-title>
<source><![CDATA[Pediatr Blood Cancer]]></source>
<year>2017</year>
<volume>64</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bebito&#287;lu]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[O&#287;uz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nuho&#287;lu]]></surname>
<given-names><![CDATA[Ç]]></given-names>
</name>
<name>
<surname><![CDATA[Dalk&#305;l&#305;ç]]></surname>
<given-names><![CDATA[AEK]]></given-names>
</name>
<name>
<surname><![CDATA[Çirtlik]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Temel]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of potential drug-drug interactions in a pediatric population]]></article-title>
<source><![CDATA[Turk Pediatri Ars]]></source>
<year>2020</year>
<volume>55</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>30-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roblek]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Vaupotic]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mrhar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lainscak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-drug interaction software in clinical practice: a systematic review]]></article-title>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2015</year>
<volume>71</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>131-42</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Easton]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Brien]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2004</year>
<volume>57</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>611-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheridan]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Burns in Children]]></article-title>
<source><![CDATA[J Burn Care Res]]></source>
<year>2017</year>
<volume>38</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>e618-24</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="book">
<collab>IBM Micromedex®</collab>
<source><![CDATA[Drug Interaction Checking]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Greenwood Village (CO) ]]></publisher-loc>
<publisher-name><![CDATA[IBM Watson Health (US)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Terol]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Caraballo]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Palma]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Santos-Ramos]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Desongles]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Calidad estructural de las bases de datos de interacciones]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2009</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>134-46</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kheshti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aalipour]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Namazi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness]]></article-title>
<source><![CDATA[J Res Pharm Pract]]></source>
<year>2016</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>257-63</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[International drug monitoring: the role of national centres. Report of a WHO meeting]]></article-title>
<source><![CDATA[World Health Organ Tech Rep Ser]]></source>
<year>1972</year>
<volume>498</volume>
<page-range>1-25</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horn]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Hansten]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proposal for a new tool to evaluate drug interaction cases]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2007</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>674-80</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartwig]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Denger]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severity-indexed, incident report-based medication error-reporting program]]></article-title>
<source><![CDATA[Am J Hosp Pharm]]></source>
<year>1991</year>
<volume>48</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2611-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oshikoya]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Oreagba]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Lawal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Awodele]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Ogunleye]]></surname>
<given-names><![CDATA[OO]]></given-names>
</name>
<name>
<surname><![CDATA[Senbanjo]]></surname>
<given-names><![CDATA[IO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential drug-drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria]]></article-title>
<source><![CDATA[HIV AIDS (Auckl)]]></source>
<year>2014</year>
<volume>6</volume>
<page-range>49-59</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz-Carrasco]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Almanchel-Rivadeneyra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tomás-Luiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pelegrín-Montesinos]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Roig]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Ávila]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Observational study of drug-drug interactions in oncological inpatients]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2018</year>
<volume>42</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>10-5</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santibáñez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Roque]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Corrales]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características de las interacciones farmacológicas en una unidad de cuidados intensivos de pediatría]]></article-title>
<source><![CDATA[Rev Chil Pediatr]]></source>
<year>2014</year>
<volume>85</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>546-53</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Gómez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Arco Prados]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisión de las interacciones farmacológicas de los fármacos antineoplásicos orales dispensados en un Servicio de Farmacia]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2014</year>
<volume>38</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>338-63</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheridan]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Burn Care for Children]]></article-title>
<source><![CDATA[Pediatr Rev]]></source>
<year>2018</year>
<volume>39</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>273-86</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oshikoya]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Oreagba]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Ogunleye]]></surname>
<given-names><![CDATA[OO]]></given-names>
</name>
<name>
<surname><![CDATA[Lawal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Senbanjo]]></surname>
<given-names><![CDATA[IO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinically significant interactions between antiretroviral and co-prescribed drugs for HIV-infected children: profiling and comparison of two drug databases]]></article-title>
<source><![CDATA[Ther Clin Risk Manag]]></source>
<year>2013</year>
<volume>9</volume>
<page-range>215-21</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
